We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02230527
Recruitment Status : Terminated (Lack of enrollment)
First Posted : September 3, 2014
Results First Posted : July 7, 2021
Last Update Posted : July 7, 2021
Information provided by (Responsible Party):
Joseph Campbell, The Cleveland Clinic

Brief Summary:
This is a single center, prospective, randomized, unblinded, open-label, active controlled pilot study to evaluate the efficacy and safety of ticagrelor plus aspirin versus clopidogrel plus aspirin in patients with Rutherford Stage IV to VI PAD that have undergone a percutaneous transluminal angioplasty (PTA) of the lower extremities in the past 2 weeks.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease Drug: Ticagrelor Drug: Clopidogrel Phase 2 Phase 3

Detailed Description:

Enrollment into the study will require severe symptomatic CLI without wounds (Rutherford Stage IV) or CLI with concomitant vascular insufficiency wounds (Rutherford Stage V-VI PAD).

Potential participants will be identified and screened prior to discharge or at the time of the first out-patient visit (within 2 weeks after discharge) after a percutaneous lower extremity arterial angiography with arterial intervention (stent or balloon angioplasty) for the presence of lower extremity vascular insufficiency. Participants will be classified as Rutherford Class IV - VI (with or without ulcerations). A total of 60 patients will be randomized into 2 treatment groups in a 1:1 ratio (ticagrelor to clopidogrel). Patients are placed on clopidogrel after their arterial intervention per standard of care. They will remain on clopidogrel up to the time that randomization occurs. For patients that are randomized to ticagrelor, the clopidogrel will be stopped.

Patients will be randomized to either ticagrelor 90mg by mouth twice daily or clopidogrel 75mg by mouth daily.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia
Actual Study Start Date : October 2014
Actual Primary Completion Date : May 2020
Actual Study Completion Date : May 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Clopidogrel
Clopidogrel 75mg by mouth daily
Drug: Clopidogrel
75mg once a day by mouth
Other Name: Plavix

Experimental: Ticagrelor
Ticagrelor 90mg by mouth twice daily
Drug: Ticagrelor
90mg twice a day by mouth
Other Names:
  • Brilinta
  • Brilique
  • Possia

Primary Outcome Measures :
  1. Absolute Change in TcPO2 From Baseline to Month 6 [ Time Frame: 6 months ]
    The primary endpoint is the absolute change in TcPO2 from baseline to month 6 compared between treatment groups.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Adults age 18-100 years with Rutherford Classification Stage IV through VI PAD with a recent percutaneous lower extremity arterial angiography with arterial intervention in the past 2 weeks
  2. Willingness to sign informed consent
  3. Ability to return for follow up visits
  4. A female patient of childbearing potential who is sexually active must agree to use adequate contraception from screening until 30 days after receiving the last dose of study drug. Women not of childbearing potential are defined as those who have surgically sterilized (hysterectomy, bilateral oophorectomy, or tubal ligation) or who are post menopausal (defined as at least 2 years since last regular menses). The female patient should not be lactating and must have a negative pregnancy test at screening.

Exclusion Criteria:

Patients will be ineligible for this study if they meet any one of the following criteria:

  1. Intolerance to thienopyridines
  2. Hypersensitivity to ticagrelor or any component of the product.
  3. Concomitant use of oral anticoagulation with vitamin K antagonist, factor Xa inhibitor, or direct thrombin inhibitor
  4. History of intracranial hemorrhage
  5. History of severe hepatic impairment defined by baseline transaminase greater than or equal to 3x ULN or any elevation in bilirubin
  6. Active bleeding
  7. Allergy to aspirin
  8. Baseline TcPO2 < 10 mmHg post angiography
  9. Resting, pre- procedure heart rate <50 beats-per-minute without a permanent pacemaker and not on an atrioventricular nodal blocking agent
  10. Severe COPD on home oxygen therapy -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02230527

Layout table for location information
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
The Cleveland Clinic
Layout table for investigator information
Principal Investigator: Joseph Campbell, MD The Cleveland Clinic
  Study Documents (Full-Text)

Documents provided by Joseph Campbell, The Cleveland Clinic:
Layout table for additonal information
Responsible Party: Joseph Campbell, Principal Investigator, The Cleveland Clinic
ClinicalTrials.gov Identifier: NCT02230527    
Other Study ID Numbers: 14-799
First Posted: September 3, 2014    Key Record Dates
Results First Posted: July 7, 2021
Last Update Posted: July 7, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Peripheral Vascular Diseases
Pathologic Processes
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs